Stock Track | Grifols Shares Soar on Strong Q3 Sales, Earnings Growth

Stock Track11-08

Shares of Spanish pharmaceuticals company Grifols SA (GRFS) surged 5.16% on Thursday, driven by the company's better-than-expected third-quarter financial results and bullish outlook.

Grifols reported a 12.2% year-over-year increase in total revenue to €1.79 billion ($1.93 billion) for the third quarter, exceeding analysts' expectations. The strong performance was fueled by the company's biopharma division, which saw robust demand for its products.

Additionally, Grifols' adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose 26.7% at constant currency to €462 million, benefiting from a favorable product mix, lower costs, and operational leverage. The company remains on track to achieve full-year revenue exceeding €7 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1146633442?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146633442","market":"us","top_or_hot":-1,"title":"Stock Track | Grifols Shares Soar on Strong Q3 Sales, Earnings Growth","media":"Stock Track","content":"<p>Shares of Spanish pharmaceuticals company Grifols SA (GRFS) surged 5.16% on Thursday, driven by the company's better-than-expected third-quarter financial results and bullish outlook.</p>\n\n<p>Grifols reported a 12.2% year-over-year increase in total revenue to €1.79 billion ($1.93 billion) for the third quarter, exceeding analysts' expectations. The strong performance was fueled by the company's biopharma division, which saw robust demand for its products.</p>\n\n<p>Additionally, Grifols' adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose 26.7% at constant currency to €462 million, benefiting from a favorable product mix, lower costs, and operational leverage. The company remains on track to achieve full-year revenue exceeding €7 billion.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Grifols Shares Soar on Strong Q3 Sales, Earnings Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Grifols Shares Soar on Strong Q3 Sales, Earnings Growth\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-08 18:44 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Spanish pharmaceuticals company Grifols SA (GRFS) surged 5.16% on Thursday, driven by the company's better-than-expected third-quarter financial results and bullish outlook.\nGrifols reported...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GRFS","symbol_name":"基立福","start_time":0,"source_url":"","article_id":"1146633442","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146633442","pubTimestamp":1731062657,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Spanish pharmaceuticals company Grifols SA  surged 5.16% on Thursday, driven by the company's better-than-expected third-quarter financial results and bullish outlook.Grifols reported a 12.2% year-over-year increase in total revenue to 1.79 billion  for the third quarter, exceeding analysts' expectations. The strong performance was fueled by the company's biopharma division, which saw robust demand for its products.Additionally, Grifols' adjusted earnings before interest, taxes, deprec","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GRFS":"基立福"},"translate_title":"股票追踪Grifols股价因第三季度强劲销售和盈利增长而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRFS":1},"content_text":"Shares of Spanish pharmaceuticals company Grifols SA (GRFS) surged 5.16% on Thursday, driven by the company's better-than-expected third-quarter financial results and bullish outlook.\nGrifols reported a 12.2% year-over-year increase in total revenue to €1.79 billion ($1.93 billion) for the third quarter, exceeding analysts' expectations. The strong performance was fueled by the company's biopharma division, which saw robust demand for its products.\nAdditionally, Grifols' adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose 26.7% at constant currency to €462 million, benefiting from a favorable product mix, lower costs, and operational leverage. The company remains on track to achieve full-year revenue exceeding €7 billion.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146633442"}